RU2019104870A - Комбинированный тест на наличие колоректального рака - Google Patents
Комбинированный тест на наличие колоректального рака Download PDFInfo
- Publication number
- RU2019104870A RU2019104870A RU2019104870A RU2019104870A RU2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A RU 2019104870 A RU2019104870 A RU 2019104870A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- cell
- colorectal cancer
- free nucleosome
- detecting
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title claims 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims 5
- 238000000034 method Methods 0.000 claims 5
- 108010047956 Nucleosomes Proteins 0.000 claims 4
- 210000001623 nucleosome Anatomy 0.000 claims 4
- 238000009534 blood test Methods 0.000 claims 3
- 230000002550 fecal effect Effects 0.000 claims 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 238000002052 colonoscopy Methods 0.000 claims 2
- 201000002758 colorectal adenoma Diseases 0.000 claims 2
- 230000001973 epigenetic effect Effects 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 230000010438 iron metabolism Effects 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 208000022131 polyp of large intestine Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000003608 fece Anatomy 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
Claims (11)
1. Способ обнаружения и/или скрининга колоректального рака (CRC), колоректальной аденомы или полипа у пациента, включающий:
(a) идентификацию пациента, имевшего положительный результат анализа фекалий на скрытую кровь; и
(b) обнаружение или измерение уровня одного или более элементов в образце крови, сыворотки или плазмы, полученном у пациента, при этом элемент выбирают из бесклеточной нуклеосомы, эпигенетического признака бесклеточной нуклеосомы, карциноэмбрионального антигена, биомаркера метаболизма железа или индуцируемого гипоксией фактора,
при этом результат, полученный на этапе (b), указывает на вероятность наличия у пациента колоректального рака (CRC), колоректальной аденомы или полипа.
2. Способ оценки пригодности пациента для колоноскопии, включающий:
(a) анализ фекалий на скрытую кровь для образца фекалий, полученного у пациента;
(b) обнаружение или измерение уровня одного или более элементов в образце крови, сыворотки или плазмы, полученном у пациента, при этом элемент выбирают из бесклеточной нуклеосомы, эпигенетического признака бесклеточной нуклеосомы, карциноэмбрионального антигена, биомаркера метаболизма железа или индуцируемого гипоксией фактора; и
(c) использование результата, полученного в (b), в качестве показателя пригодности пациента для колоноскопии.
3. Способ по любому из пп. 1 и 2, который дополнительно включает в себя использование численного результата анализа фекалий на скрытую кровь в качестве параметра на этапе (b).
4. Способ по любому из пп. 1-3, который дополнительно включает использование клинического параметра на этапе (b).
5. Способ по п. 4, в котором клинический параметр выбирают из возраста, пола и индекса массы тела (ИМТ).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1612815.9A GB201612815D0 (en) | 2016-07-25 | 2016-07-25 | Novel combination test |
| GB1612815.9 | 2016-07-25 | ||
| PCT/EP2017/068754 WO2018019827A1 (en) | 2016-07-25 | 2017-07-25 | Combination test for colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019104870A true RU2019104870A (ru) | 2020-08-25 |
| RU2019104870A3 RU2019104870A3 (ru) | 2020-12-01 |
Family
ID=56894403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019104870A RU2019104870A (ru) | 2016-07-25 | 2017-07-25 | Комбинированный тест на наличие колоректального рака |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200182875A1 (ru) |
| EP (1) | EP3488238B1 (ru) |
| JP (1) | JP6983221B2 (ru) |
| KR (1) | KR102442803B1 (ru) |
| CN (1) | CN109791154A (ru) |
| AU (1) | AU2017301970B2 (ru) |
| BR (1) | BR112019001384A2 (ru) |
| CA (1) | CA3031580A1 (ru) |
| GB (1) | GB201612815D0 (ru) |
| IL (1) | IL264359B2 (ru) |
| MY (1) | MY193895A (ru) |
| RU (1) | RU2019104870A (ru) |
| SG (2) | SG10202100630SA (ru) |
| TW (1) | TWI776816B (ru) |
| WO (1) | WO2018019827A1 (ru) |
| ZA (1) | ZA201808601B (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021024009A1 (en) * | 2019-08-02 | 2021-02-11 | Shanghai Yunxiang Medical Technology Co., Ltd. | Methods and compositions for providing colon cancer assessment using protein biomarkers |
| CN112345766B (zh) * | 2020-10-22 | 2024-02-02 | 中国工程物理研究院核物理与化学研究所 | 一种荧光-放射性联用的体外靶向筛选方法 |
| TW202242146A (zh) * | 2021-01-13 | 2022-11-01 | 比利時商比利時意志有限公司 | 肺癌的檢測方法 |
| US20240118282A1 (en) * | 2021-02-11 | 2024-04-11 | Herbert A. Fritsche | Kits and methods for detecting markers and determining the presence or risk of cancer |
| CN116718775B (zh) * | 2023-08-04 | 2023-10-27 | 天津迈基生物科技有限公司 | 一种检测结直肠癌的组合物、试纸及方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010089538A2 (en) * | 2009-02-03 | 2010-08-12 | Oncomethylome Sciences Sa | Methods of detecting colorectal cancer |
| BRPI1013546A2 (pt) * | 2009-04-14 | 2019-04-09 | The Regente Of The University Of California | usos de um inibidor da timidilato sintase e de uma terapia anticâncer |
| US8568984B2 (en) * | 2010-02-19 | 2013-10-29 | Philadelphia Health & Education Corporation | Methods of diagnosing non-urinary tract diseases by detecting aberrant methylation |
| JP2012018119A (ja) * | 2010-07-09 | 2012-01-26 | Toray Ind Inc | 大腸癌検出用マーカーおよびそれを用いた大腸癌検出方法 |
| WO2012017208A1 (en) * | 2010-08-04 | 2012-02-09 | Cizzle Biotechnology Limited | Methods and compounds for the diagnosis and treatment of |
| GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| WO2013084002A2 (en) * | 2011-12-07 | 2013-06-13 | Singapore Volition Pte Limited | Method for detecting nucleosome adducts |
| CA3083314C (en) * | 2012-05-11 | 2023-01-31 | Clinical Genomics Pty Ltd | Diagnostic gene marker panel for colorectal cancer |
-
2016
- 2016-07-25 GB GBGB1612815.9A patent/GB201612815D0/en not_active Ceased
-
2017
- 2017-07-25 SG SG10202100630SA patent/SG10202100630SA/en unknown
- 2017-07-25 MY MYPI2019000398A patent/MY193895A/en unknown
- 2017-07-25 KR KR1020197002048A patent/KR102442803B1/ko active IP Right Grant
- 2017-07-25 AU AU2017301970A patent/AU2017301970B2/en active Active
- 2017-07-25 SG SG11201900329XA patent/SG11201900329XA/en unknown
- 2017-07-25 EP EP17743043.6A patent/EP3488238B1/en active Active
- 2017-07-25 IL IL264359A patent/IL264359B2/en unknown
- 2017-07-25 RU RU2019104870A patent/RU2019104870A/ru unknown
- 2017-07-25 WO PCT/EP2017/068754 patent/WO2018019827A1/en unknown
- 2017-07-25 BR BR112019001384-9A patent/BR112019001384A2/pt unknown
- 2017-07-25 CN CN201780045694.2A patent/CN109791154A/zh active Pending
- 2017-07-25 TW TW106124811A patent/TWI776816B/zh active
- 2017-07-25 JP JP2019503672A patent/JP6983221B2/ja active Active
- 2017-07-25 US US16/320,440 patent/US20200182875A1/en not_active Abandoned
- 2017-07-25 CA CA3031580A patent/CA3031580A1/en active Pending
-
2018
- 2018-12-20 ZA ZA2018/08601A patent/ZA201808601B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3488238B1 (en) | 2023-06-07 |
| TWI776816B (zh) | 2022-09-11 |
| CA3031580A1 (en) | 2018-02-01 |
| ZA201808601B (en) | 2019-09-25 |
| TW201804156A (zh) | 2018-02-01 |
| AU2017301970A1 (en) | 2019-01-17 |
| IL264359B2 (en) | 2024-03-01 |
| MY193895A (en) | 2022-10-31 |
| RU2019104870A3 (ru) | 2020-12-01 |
| JP6983221B2 (ja) | 2021-12-17 |
| EP3488238A1 (en) | 2019-05-29 |
| CN109791154A (zh) | 2019-05-21 |
| JP2019527361A (ja) | 2019-09-26 |
| IL264359A (en) | 2019-02-28 |
| AU2017301970B2 (en) | 2023-04-27 |
| BR112019001384A2 (pt) | 2019-04-30 |
| KR102442803B1 (ko) | 2022-09-15 |
| EP3488238C0 (en) | 2023-06-07 |
| SG10202100630SA (en) | 2021-03-30 |
| WO2018019827A1 (en) | 2018-02-01 |
| KR20190039089A (ko) | 2019-04-10 |
| SG11201900329XA (en) | 2019-02-27 |
| US20200182875A1 (en) | 2020-06-11 |
| IL264359B1 (en) | 2023-11-01 |
| GB201612815D0 (en) | 2016-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019104870A (ru) | Комбинированный тест на наличие колоректального рака | |
| Kaczor‐Urbanowicz et al. | Emerging technologies for salivaomics in cancer detection | |
| Qi et al. | Circulating long non-coding RNAs in cancer: current status and future perspectives | |
| Chou et al. | Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis | |
| Shah et al. | Biomarkers for early detection of colorectal cancer and polyps: systematic review | |
| Lee et al. | Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in hepatocellular carcinoma (HCC) | |
| CY1126069T1 (el) | Προσδιορισμος για αντισωματα ιου jc | |
| US20180080937A1 (en) | Biomarker Panel For Diagnosing Cancer | |
| JP2008542703A5 (ru) | ||
| RU2014112350A (ru) | Способ детекции нуклеосом, содержащих нуклеотиды | |
| Yang et al. | Dickkopf-1: as a diagnostic and prognostic serum marker for early hepatocellular carcinoma | |
| JP2016500110A5 (ru) | ||
| JP2018504609A5 (ru) | ||
| Yazbeck et al. | From blood to breath: New horizons for esophageal cancer biomarkers | |
| Pardi et al. | Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? | |
| JP2019527361A5 (ru) | ||
| WO2015100459A3 (en) | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies | |
| JP2011508197A5 (ru) | ||
| Bilegsaikhan et al. | Circulating miR‐338‐5p is a potential diagnostic biomarker in colorectal cancer | |
| Creeden et al. | Serum tests for colorectal cancer screening | |
| Alkotyfan et al. | Cyfra 21-1 as a Tumor Marker for Follow-up of Patients with Squamous Cell Carcinoma of the Oropharnyx | |
| CY1119797T1 (el) | Λακτοφερινη για χρηση στη διαγνωση και προγνωση της νοσου alzheimer | |
| JP2020514689A5 (ru) | ||
| Kammer et al. | Noninvasive biomarkers for lung cancer diagnosis, where do we stand? | |
| Gonzalez | Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? |